Physiological Effect: Decreased RNA Integrity

Drugs with Physiological Effect: Decreased RNA Integrity

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes	8,101,743		Y	Y
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes	10,683,499		Y	Y
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes	9,127,276			Y
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes	9,181,549			Y
Astrazeneca Ab	WAINUA	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-002	Apr 15, 2026		RX	Yes	Yes

Last updated: July 7, 2026

Market dynamics and patent landscape for drugs that decrease RNA integrity: What’s protected, who’s challenging, and when generics can enter?

Drugs whose physiological effect is “decreased RNA integrity” sit at the intersection of oncology RNA-damage and immunology RNA-disruption mechanisms. The market dynamics are dominated by (1) whether the agent is an NRTI-like nucleoside that perturbs RNA synthesis, (2) whether it is an RNA-binding or RNA-modulating drug that triggers RNA degradation, and (3) the depth of the patent estate around salts, polymorphs, prodrugs, delivery systems, and dosing regimens. Patent risk is typically concentrated in process and formulation claims, with primary composition-of-matter protection often complemented by method-of-use claims that can block generic substitution even after core expiry.

What patents protect drugs that decrease RNA integrity (RNA degradation, RNA fragmentation, or RNA damage)?

Featured snippet answer: Patent coverage usually spans (a) nucleoside analogs or RNA-targeting compounds (composition of matter), (b) specific prodrugs/salts/polymorphs, (c) manufacturing/process claims for API and intermediates, and (d) method-of-use regimens that tie the RNA-integrity lowering mechanism to a therapeutic outcome.

Which mechanism categories most often map to “decreased RNA integrity”?

The patent and regulatory landscape differs by mechanism class. The most common buckets include:

• Nucleoside analogs that disrupt nucleic acid metabolism
  Claims typically cover compound structure, stereochemistry, salts, and prodrug moieties; method-of-use often targets viral replication or proliferative disease models tied to RNA synthesis impairment.

• Small molecules or biologics that bind RNA or RNA-associated complexes
  Patent estates skew toward composition-of-matter and method-of-use; formulation and route-of-administration claims can be critical for differentiation.

• Agents that induce RNA damage through oxidative or catalytic pathways
  Patent coverage often focuses on specific chemical entities plus delivery to relevant tissues, with downstream composition and combination regimens.

How many patents usually cover the “RNA integrity lowering” concept?

Patent estates for RNA-disrupting drugs typically include multiple layers:

• Core composition-of-matter: 1 to 5 families per active
• Salt/polymorph/prodrug variants: 1 to 8 families
• Formulation and delivery: 1 to 10 families (especially for oral bioavailability or sustained release)
• Method-of-use (dose, schedule, patient selection): 3 to 15 families
• Combination therapy: 2 to 10 families
• Manufacturing and intermediates: 5 to 25 patents across jurisdictions

What claim types block generic entry when “RNA integrity” is the mechanism?

Even where composition-of-matter expires, generic launch risk remains high when the Orange Book lists:

• Method-of-use patents (for specific indication, line of therapy, or patient population)
• Formulation patents (critical dose uniformity, release profile, or excipient system)
• Combination patents (co-administered drug and dosing schedule)

Where are “RNA integrity” mechanism patents concentrated geographically?

High-stakes filings usually concentrate in:

• US (composition, method-of-use, Orange Book listings)
• EP (validity and injunctive leverage)
• JP and CN (manufacturing and localized enforcement value)
• KR and CA selectively, depending on commercialization partners

When does RNA-integrity-lowering exclusivity end: How long is the protection runway?

Featured snippet answer: The runway is set by the latest of (1) patent expiration (including patent term adjustments and extensions), (2) pediatric exclusivity where applicable, and (3) regulatory exclusivity (NCE or new clinical investigation). For RNA-integrity drugs, the effective cliff often comes from the newest formulation or method-of-use patent family listed in the Orange Book rather than the earliest composition patent.

What drives exclusivity timing in the US?

Typical US exclusivity components for small-molecule drugs:

• Patent term (20 years from earliest effective filing, adjusted for PTA and subject to extensions)
• Patent term adjustment (PTA) if granted by USPTO
• Patent term extension for regulatory delays, if eligible
• 5-year NCE data exclusivity (new chemical entity) or 3-year exclusivity for new clinical investigations
• Up to 6 months pediatric exclusivity triggered by FDA requirements

How to read “effective expiry” for RNA-integrity drugs

For generics and biosimilar-like small molecules, the relevant date is:

• Latest expiring listed patent that the FDA applicant must carve around (Orange Book)
• Latest blocking method-of-use patent tied to the labeled indication

In practice, the generic launch window often opens only after:

• Composition-of-matter expires
• Method-of-use patents listed in Orange Book expire or are invalidated
• Any settlement with Paragraph IV filers lifts any negotiated non-infringement or “60-day first filer” constraints

Timeline template used in market-entry modeling

Use a three-stage model:

1. Patent cliff: latest composition/prodrug/formulation/method-of-use expiry
2. Litigation cliff: settlement or final court decision that removes injunction risk
3. Exclusivity cliff: FDA exclusivity expiration (data and pediatric) that blocks certain ANDA paths

What generic entry risks exist for drugs that decrease RNA integrity?

Featured snippet answer: The largest entry risks for generic manufacturers come from method-of-use and formulation patents listed in the Orange Book, plus process restrictions for key intermediates and prodrugs. Composition-of-matter expiry alone rarely guarantees freedom to operate.

Paragraph IV challenges: what most often gets attacked

In RNA-integrity drugs, ANDA Paragraph IV filings commonly target:

• Specific salt forms or polymorphs
• Prodrug conversion intermediates
• Method-of-use patents that prescribe a dosing schedule tied to efficacy endpoints
• Combination regimen patents

Settlement dynamics that affect market entry

When settlements occur, they tend to include:

• Launch date commitments (delayed entry)
• Carve-outs for specific strengths, dosage forms, or indication subsets
• Stipulations not to market until a date tied to the last blocking patent expiry

180-day exclusivity for first filers: how it plays out

First-filer exclusivity can be meaningful, but it is frequently constrained by:

• Court outcomes on patent validity or infringement
• Shared Orange Book listings across multiple ANDAs
• “Design-around” strategies that change dosage form or strength, potentially avoiding infringement

Which companies are challenging RNA-integrity-lowering drugs, and what litigation matters?

Featured snippet answer: The litigation set is determined by (a) whether an Orange Book patent blocks the labeled indication and (b) whether generics can design around formulation/method-of-use without triggering infringement. Challengers usually cluster around large-revenue brands with multi-layer patent lists.

Common litigation pathways in this mechanism class

• ANDA Paragraph IV actions in Delaware, Massachusetts, New Jersey, or DC
• ITC import exclusion actions tied to patent infringement
• Civil actions on injunction entitlement and validity

What litigation facts drive market outcomes

• Whether the case is decided on “non-infringement” vs “invalidity”
• Whether injunctions are entered and stayed pending appeal
• Whether a settlement includes partial carve-outs that preserve brand revenue

What is the Orange Book status of RNA-integrity-lowering drugs?

Featured snippet answer: Orange Book status determines ANDA risk. For RNA-integrity drugs, expect multi-layer listings across:

• Drug substance and drug product patents
• Methods of use (for key indications)
• Formulation patents (dose form and delivery)

How to interpret Orange Book listings for launch modeling

Key inputs to model:

• Listed patent numbers and expiry dates
• Patent type (drug substance, drug product, method of use)
• Whether the ANDA is subject to “section viii” certifications (carve-outs)
• Whether multiple patents cover the same label claim, multiplying litigation and settlement complexity

How Orange Book listings correlate with revenue protection

Brands with deep method-of-use and formulation listings often sustain market exclusivity longer through:

• Multiple sequential settlements with different first filers
• Narrow generic design work that can still infringe
• Enforcement on product claims tied to the approved formulation

What formulations are protected when a drug decreases RNA integrity?

Featured snippet answer: Formulation patents for RNA-integrity drugs often cover the practical differences that enable generic products to avoid infringement and substitution, including salt form selection, solid-state form control, particle size distribution, dissolution profile, and prodrug stabilization.

Typical formulation patent targets

• Salts and co-crystals that control solubility and stability
• Polymorphs and amorphous forms with defined PXRD/DSC signatures
• Prodrug formulations that manage conversion kinetics
• Controlled-release matrices and encapsulation systems
• Excipients affecting RNA integrity-related therapeutic exposure windows

How delivery system patents affect generic development time

Delivery system IP can extend lead times because generic applicants must match:

• Dissolution and exposure profiles
• Bioequivalence metrics that are harder with modified-release systems
• Stability and shelf-life claims that support regulatory and enforcement positions

How strong is the patent estate for drugs that decrease RNA integrity?

Featured snippet answer: Patent strength is typically measured by the number of independent composition families, the presence of long-lived method-of-use and formulation patents, and the litigation/administrative survival of similar claims in the same chemistry class.

Patent estate strength indicators used by investors and counsel

• Number of Orange Book-listed method-of-use patents for the labeled indication
• Breadth of claim coverage (genus vs species; functional claims vs narrow structures)
• Presence of multiple jurisdictions with parallel filings
• Evidence of enforceability through earlier court survival or settlement leverage

Common weakness patterns in these estates

• Overly broad functional claims that get narrowed in prosecution
• Species claims dependent on narrow experimental data
• Process claims that become non-unique as manufacturing matures

How do RNA-integrity-lowering drugs compare with adjacent mechanisms (RNA synthesis inhibitors, RNA binding agents, NRTIs)?

Featured snippet answer: Adjacent mechanism classes overlap on “RNA disruption” outcomes, but patent estates and design-around paths differ. NRTI-like compounds have well-populated chemical space and many derivative patents; RNA-binding agents have more variable claim boundaries tied to target biology; RNA-damage inducers can have broader process and combination claim strategies.

Competitive differentiation that changes patent risk

• If clinical efficacy ties to a specific RNA target or biomarker, method-of-use claims strengthen
• If outcomes depend mostly on systemic exposure, formulation and PK matching patents matter
• If efficacy is tied to a combination regimen, combination patents drive generic delay

What patent litigation affects RNA-integrity-lowering drugs (injunctions, design-arounds, and ITC risk)?

Featured snippet answer: Litigation risk compounds when patents cover both the compound and the approved regimen. Brand leverage increases with injunction likelihood, while generic leverage increases with viable design-around routes that avoid both composition and method-of-use infringement.

High-impact litigation events for market timing

• Denial or grant of preliminary injunctions
• Claim construction decisions that narrow infringement reach
• Settlement that converts litigation into delayed launch commitments
• Final judgments that affect remaining patents in the family

ITC actions: when they matter commercially

ITC risk is highest when:

• The infringing product can be imported at scale pre-launch
• The brand seeks faster pressure on supply chains
• Multiple patents have strong infringement positions

Key Takeaways

• “Decreased RNA integrity” drugs typically rely on multi-layer patent estates: composition, salt/polymorph/prodrug variants, formulation/delivery, and method-of-use regimen claims.
• Market entry timing is usually governed by the latest Orange Book-listed blocking patents, not the earliest composition expiry.
• Paragraph IV and design-around strategies often focus on salt/polymorph/prodrug and method-of-use claim carve-outs, with settlement terms frequently dictating real-world launch.
• Patent strength tracks Orange Book depth and the survivability of method-of-use and formulation claims in litigation and prosecution.

FAQs

1. Which Orange Book patent types most often block ANDA entry for RNA-integrity-lowering drugs?
2. Do settlements for Paragraph IV challenges typically delay all strengths or only specific dosage forms for RNA-integrity agents?
3. How do prodrug and polymorph patent families change the design-around path for generic manufacturers?
4. What biomarkers or mechanism-linked clinical endpoints most often appear in method-of-use claims tied to RNA integrity?
5. When can a generic launch despite composition-of-matter expiry if method-of-use patents remain listed?

References

1. [No cited sources provided in the prompt]